MATRIX METALLOPROTEINASE-2 IN BONE MARROW OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODISPLASTIC SYNDROME

I.F. Lesnichenko, S.V. Gritsaev, I.I. Kostroma, A.V. Chechetkin
Russian Research Institute of Hematology and Transfusiology of FMBA,
2-nd Sovetskaya str., 16, St-Petersburg, 191023, Russian Federation
E-mail: gritsaevsv@mail.ru

Introduction. Search for correct markers for diagnosis, prognosis and evaluation of the effectiveness of chemotherapy is the most important problem of the modern oncohematology. The aim. To determine the clinical relevance of matrix metalloproteinase-2 (MMP-2) level in bone marrow plasma in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Methods. The MMP-2 level in bone marrow plasma was determined with immunoassay kits «Human MMP-2 immunoassay» (R&D Systems, USA). Results. There were no significant differences in the MMP-2 levels between MDS and active AML patients. At the same time MDS and AML patients without the complete remission had MMP-2 levels significantly lower than AML patients in the complete remission. There was observed the gain in MMP-2 levels after the successful therapy and decreasing of them after the beginning of the relapse. Conclusion. The level of MMP-2 in bone marrow plasma may be considered as promising index for the evaluation of the effectiveness of the therapy in AML and MDS patients. MMP-2 can be considered to participate in leukemogenesis.
Keywords: 
matrix metalloproteinase-2, acute myeloid leukemia, myelodysplastic syndrome